TY-1091

News alerts, weekly reports and conference planners

Company:

TYK Medicines

Drug class:

RET inhibitor

Related drugs:

RET C634W	Thyroid Gland Carcinoma	RET C634W	Thyroid Gland Carcinoma	TY-1091 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) TY-1091 Sensitive : D AACR 2023 - 1wk	TY-1091 Sensitive: D – Preclinical AACR 2023 - 1 week TY-1091 Sensitive : D AACR 2023 - 1 week - (New D)
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	TY-1091 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) TY-1091 Sensitive : D AACR 2023 - 1wk	TY-1091 Sensitive: D – Preclinical AACR 2023 - 1 week TY-1091 Sensitive : D AACR 2023 - 1 week - (New D)

Associations
(2)